Mesoporous systems for poorly soluble drugs

被引:203
作者
Xu, Wujun [1 ]
Riikonen, Joakim [1 ]
Lehto, Vesa-Pekka [1 ]
机构
[1] Univ Eastern Finland, Dept Appl Phys, FI-70211 Kuopio 70211, Finland
关键词
Mesoporous inorganic materials; Drug delivery; Enhanced dissolution; Bioavailability; POROUS SILICON NANOPARTICLES; PORE-SIZE CONTROL; ORAL BIOAVAILABILITY; SURFACE FUNCTIONALIZATION; SOLID DISPERSIONS; FACILE SYNTHESIS; PHYSICAL STATE; PARTICLE-SIZE; DELIVERY; RELEASE;
D O I
10.1016/j.ijpharm.2012.09.008
中图分类号
R9 [药学];
学科分类号
100702 [药剂学];
摘要
Utilization of inorganic mesoporous materials in formulations of poorly water-soluble drugs to enhance their dissolution and permeation behavior is a rapidly growing area in pharmaceutical materials research. The benefits of mesoporous materials in drug delivery applications stem from their large surface area and pore volume. These properties enable the materials to accommodate large amounts of payload molecules, protect them from premature degradation, and promote controlled and fast release. As carriers with various morphologies and chemical surface properties can be produced, these materials may even promote adsorption from the gastrointestinal tract to the systemic circulation. The main concern regarding their clinical applications is still the safety aspect even though most of them have been reported to be safely excreted, and a rather extensive toxicity screening has already been conducted with the most frequently studied mesoporous materials. In addition, the production of the materials on a large scale and at a reasonable cost may be a challenge when considering the utilization of the materials in industrial processes. However, if mesoporous materials could be employed in the industrial crystallization processes to produce hybrid materials with poorly soluble compounds, and hence to enhance their oral bioavailability, this might open new avenues for the pharmaceutical industry to employ nanotechnology in their processes. (c) 2012 Elsevier B.V. All rights reserved.
引用
收藏
页码:181 / 197
页数:17
相关论文
共 144 条
[1]
Interaction of an ordered mesoporous bioactive glass with osteoblasts, fibroblasts and lymphocytes, demonstrating its biocompatibility as a potential bone graft material [J].
Alcaide, M. ;
Portoles, P. ;
Lopez-Noriega, A. ;
Arcos, D. ;
Vallet-Regi, M. ;
Portoles, M. T. .
ACTA BIOMATERIALIA, 2010, 6 (03) :892-899
[2]
Encapsulation of poorly soluble basic drugs into enteric microparticles: A novel approach to enhance their oral bioavailability [J].
Alhnan, Mohamed A. ;
Murdan, Sudaxshina ;
Basit, Abdul W. .
INTERNATIONAL JOURNAL OF PHARMACEUTICS, 2011, 416 (01) :55-60
[3]
Use of SBA-15 for furosemide oral delivery enhancement [J].
Ambrogi, Valeria ;
Perioli, Luana ;
Pagano, Cinzia ;
Marmottini, Fabio ;
Ricci, Maurizio ;
Sagnella, Anna ;
Rossi, Carlo .
EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES, 2012, 46 (1-2) :43-48
[4]
Dissolution of different forms of partially porous silicon wafers under simulated physiological conditions [J].
Anderson, SHC ;
Elliott, H ;
Wallis, DJ ;
Canham, LT ;
Powell, JJ .
PHYSICA STATUS SOLIDI A-APPLICATIONS AND MATERIALS SCIENCE, 2003, 197 (02) :331-335
[5]
Influences of material characteristics on ibuprofen drug loading and release profiles from ordered micro- and mesoporous silica matrices [J].
Andersson, J ;
Rosenholm, J ;
Areva, S ;
Lindén, M .
CHEMISTRY OF MATERIALS, 2004, 16 (21) :4160-4167
[6]
Drug delivery from structured porous inorganic materials [J].
Arruebo, Manuel .
WILEY INTERDISCIPLINARY REVIEWS-NANOMEDICINE AND NANOBIOTECHNOLOGY, 2012, 4 (01) :16-30
[7]
Solid-state NMR study of ibuprofen confined in MCM-41 material [J].
Azais, Thierry ;
Tourne-Peteilh, Corine ;
Aussenac, Fabien ;
Baccile, Niki ;
Coelho, Cristina ;
Devoisselle, Jean-Marie ;
Babonneau, Florence .
CHEMISTRY OF MATERIALS, 2006, 18 (26) :6382-6390
[8]
Solid state NMR characterisation of encapsulated molecules in mesoporous silica [J].
Babonneau, F ;
Yeung, L ;
Steunou, N ;
Gervais, C ;
Ramila, A ;
Vallet-Regi, M .
JOURNAL OF SOL-GEL SCIENCE AND TECHNOLOGY, 2004, 31 (1-3) :219-223
[9]
Bayliss SC, 1999, ADV MATER, V11, P318, DOI 10.1002/(SICI)1521-4095(199903)11:4<318::AID-ADMA318>3.0.CO
[10]
2-Z